Compound Libraries

Companies Compound Libraries

News Compound Libraries

• Sigma-Aldrich Acquires ChemNavigator, Inc.

  Sigma-Aldrich announced the acquisition of cheminformatics company, ChemNavigator .com, Incorporated, a provider of discovery research informatics software tools used for design, selection and procurement of chemical compound libraries. The acquisition links ChemNavigator's suite of virtual screenin more

• Galapagos sells San Diego chemistry facility to ChemVentures

  Galapagos NV announced that it has completed the sale of its BioFocus DPI chemistry facility in San Diego to ChemVentures Pty Ltd, an Australian discovery research group. Financial terms were not disclosed. The San Diego facility currently employs 40 people and provides medicinal chemistry and cu more

• ChemDiv to Supply Italien Nerviano Medical Sciences with Discovery Chemical Libraries

  ChemDiv, Inc. and Nerviano Medical Sciences (NervianoMS), Milano, Italy, announced an extension of their collaboration to an additional 2 year program. NervianoMS will use services of ChemDiv for building and enriching its portfolio of proprietary discovery chemical libraries. Such compound librarie more

Publications Compound Libraries

• Scaffold-Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitors

  We describe and apply a scaffold-focused virtual screen based upon scaffold trees to the mitotic kinase TTK (MPS1). Using level 1 of the scaffold tree, we perform both 2D and 3D similarity searches between a query scaffold and a level 1 scaffold library derived from a 2 million compound library; 98 more

• Oxadiazole-isopropylamides as Potent and Noncovalent Proteasome Inhibitors

  Screening of the 50 000 ChemBridge compound library led to the identification of the oxadiazole-isopropylamide 1 (PI-1833) which inhibited chymotrypsin-like (CT-L) activity (IC50 = 0.60 μM) with little effects on the other two major proteasome proteolytic activities, trypsin-like (T-L) and postgluta more

• Synthesis and in vitro Evaluation of West Nile Virus Protease Inhibitors Based on the 2‐{6‐[2‐(5‐Phenyl‐4H‐{1,2,4]triazol‐3‐ylsulfanyl)acetylamno]benzothiazol‐2‐ylsulfanyl}acet ...

  Abstract In recent years, clinical symptoms resulting from West Nile virus (WNV) infection have worsened in severity, with an increased frequency in neuroinvasive diseases among the elderly. As there are presently no successful therapies against WNV for use in humans, continual efforts to develo more

Websites Compound Libraries